NCT04312347View on ClinicalTrials.gov

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

NACompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

June 30, 2021

Conditions

ER+ Breast Cancer

Interventions

DRUG

Tamoxifen dose adjustment

Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.

Trial Locations (1)

12930

MRCCC Siloam Hospital Semanggi, Jakarta

All Listed Sponsors

lead

Nalagenetics Pte Ltd

INDUSTRY

NCT04312347 - Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels | Biotech Hunter | Biotech Hunter